Literature DB >> 27535200

Current epidemiology of tetanus in England, 2001-2014.

S Collins1, G Amirthalingam1, N J Beeching2, M A Chand3, G Godbole3, M E Ramsay1, N K Fry4, J M White1.   

Abstract

Public Health England conducts enhanced national surveillance of tetanus, a potentially life-threatening vaccine-preventable disease. A standardized questionnaire was used to ascertain clinical and demographic details of individuals reported with clinically suspected tetanus. The 96 cases identified between 2001 and 2014 were analysed. The average annual incidence was 0·13/million (95% confidence interval 0·10-0·16) of which 50·0% were male. Where reported, 70·3% of injuries occurred in the home/garden (45/64). Overall, 40·3% (31/77) cases were in people who inject drugs (PWID), including a cluster of 22 cases during 2003-2004. Where known (n = 68), only 8·8% were age-appropriately immunized. The overall case-fatality rate was 11·0% (9/82). All tetanus-associated deaths occurred in adults aged >45 years, none of whom were fully immunized. Due to the success of the childhood immunization programme, tetanus remains a rare disease in England with the majority of cases occurring in older unimmunized or partially immunized adults. Minor injuries in the home/garden were the most commonly reported likely sources of infection, although cases in PWID increased during this period. It is essential that high routine vaccine coverage is maintained and that susceptible individuals, particularly older adults, are protected through vaccination and are offered timely post-exposure management following a tetanus-prone wound.

Entities:  

Keywords:  Epidemiology; outcome; tetanus; vaccination

Year:  2016        PMID: 27535200      PMCID: PMC9150215          DOI: 10.1017/S095026881600128X

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  4 in total

1.  Preventing and treating tetanus.

Authors:  C L Thwaites; J J Farrar
Journal:  BMJ       Date:  2003-01-18

2.  Immunity to tetanus and diphtheria in the UK in 2009.

Authors:  Karen S Wagner; Joanne M White; Nick J Andrews; Ray Borrow; Elaine Stanford; Emma Newton; Richard G Pebody
Journal:  Vaccine       Date:  2012-09-26       Impact factor: 3.641

Review 3.  Maternal and neonatal tetanus.

Authors:  C Louise Thwaites; Nicholas J Beeching; Charles R Newton
Journal:  Lancet       Date:  2014-08-19       Impact factor: 79.321

4.  Tetanus in England and Wales, 1984-2000.

Authors:  A A Rushdy; J M White; M E Ramsay; N S Crowcroft
Journal:  Epidemiol Infect       Date:  2003-02       Impact factor: 2.451

  4 in total
  2 in total

1.  Letter to the Editor: New guidelines about tetanus vaccination schedules in Europe should be evaluated with caution; Comment on: Tetanus vaccination, antibody persistence and decennial booster: a serosurvey of university students and at-risk workers. By Borrella-Venturini et al.

Authors:  C Eldin; H Khalouta; Y Vitasse; M Million; P Brouqui
Journal:  Epidemiol Infect       Date:  2017-08-14       Impact factor: 4.434

Review 2.  Tetanus-diphtheria-acellular pertussis vaccination for adults: an update.

Authors:  Hyo-Jin Lee; Jung-Hyun Choi
Journal:  Clin Exp Vaccine Res       Date:  2017-01-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.